A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

November 13, 2025 updated by: Samsung Bioepis Co., Ltd.

A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 (Proposed Pembrolizumab Biosimilar) and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is:

• How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks.

Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
555

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Bosnia and Herzegovina
      • Banja Luka, Bosnia and Herzegovina
        • SB Investigative Site
      • Mostar, Bosnia and Herzegovina
        • SB Investigative Site
      • Sarajevo, Bosnia and Herzegovina
        • SB Investigative Site
  • Brazil
      • Curitiba, Brazil
        • SB Investigative Site
      • Florianópolis, Brazil
        • SB Investigative Site
      • Ijuí, Brazil
        • SB Investigative Site
      • Natal, Brazil
        • SB Investigative Site
      • Pelotas, Brazil
        • SB Investigative Site
      • Porto Alegre, Brazil
        • SB Investigative Site 1
      • Porto Alegre, Brazil
        • SB Investigative Site 2
      • Rio de Janeiro, Brazil
        • SB Investigative Site
      • Santo André, Brazil
        • SB Investigative Site
  • Georgia
      • Batumi, Georgia
        • SB Investigative Site
      • Tbilisi, Georgia
        • SB Investigative Site 1
      • Tbilisi, Georgia
        • SB Investigative Site 2
      • Tbilisi, Georgia
        • SB Investigative Site 3
      • Tbilisi, Georgia
        • SB Investigative Site 4
      • Tbilisi, Georgia
        • SB Investigative Site 5
      • Tbilisi, Georgia
        • SB Investigative Site 6
  • Germany
      • Düsseldorf, Germany
        • SB Investigative Site
      • Halle, Germany
        • SB Investigative Site
      • Moers, Germany
        • SB Investigative Site
      • Neuss, Germany
        • SB Investigative Site
  • India
      • Bangalore, India
        • SB Investigative Site
      • Bhubaneshwar, India
        • SB Investigative Site
      • Bhubaneswar, India
        • SB Investigative Site
      • Erandwane, India
        • SB Investigative Site
      • Hyderabad, India
        • SB Investigative Site
      • Jaipur, India
        • SB Investigative Site 1
      • Jaipur, India
        • SB Investigative Site 2
      • Mumbai, India
        • SB Investigative Site
      • Sūrat, India
        • SB Investigative Site
      • Udaipur, India
        • SB Investigative Site
  • Japan
      • Himeji, Japan
        • SB Investigative Site
      • Iwakuni, Japan
        • SB Investigative Site
      • Izumi, Japan
        • SB Investigative Site
      • Kawachi-Nagano, Japan
        • SB Investigative Site
      • Kobe, Japan
        • SB Investigative Site
      • Kochi, Japan
        • SB Investigative Site
      • Sagamihara, Japan
        • SB Investigative Site
      • Tachikawa, Japan
        • SB Investigative Site
      • Takarazuka, Japan
        • SB Investigative Site
      • Toyonaka, Japan
        • SB Investigative Site
  • Malaysia
      • George Town, Malaysia
        • SB Investigative Site
      • Johor Bahru, Malaysia
        • SB Investigative Site
      • Kota Bharu, Malaysia
        • SB Investigative Site
      • Kuantan, Malaysia
        • SB Investigative Site
      • Lembah Pantai, Malaysia
        • SB Investigative Site
      • Putrajaya, Malaysia
        • SB Investigative Site
  • Mexico
      • Aguascalientes, Mexico
        • SB Investigative Site
      • Guadalajara, Mexico
        • SB Investigative Site
      • Mexico City, Mexico
        • SB Investigative Site
  • Philippines
      • Davao City, Philippines
        • SB Investigative Site
      • Makati City, Philippines
        • SB Investigative Site
      • Manila, Philippines
        • SB Investigative Site
      • Quezon City, Philippines
        • SB Investigative Site
      • San Juan City, Philippines
        • SB Investigative Site
  • Romania
      • Cluj-Napoca, Romania
        • SB Investigative Site
      • Craiova, Romania
        • SB Investigative Site 1
      • Craiova, Romania
        • SB Investigative Site 2
      • Craiova, Romania
        • SB Investigative Site
      • Iași, Romania
        • SB Investigative Site
      • Oradea, Romania
        • SB Investigative Site
      • Sibiu, Romania
        • SB Investigative Site
      • Suceava, Romania
        • SB Investigative Site
  • Serbia
      • Belgrade, Serbia
        • SB Investigative Site 1
      • Belgrade, Serbia
        • SB Investigative Site 2
      • Kamenitz, Serbia
        • SB Investigative Site
      • Kragujevac, Serbia
        • SB Investigative Site
      • Niš, Serbia
        • SB Investigative Site
  • Spain
      • Leganés, Spain
        • SB Investigative Site
      • Málaga, Spain
        • SB Investigative Site
      • Ourense, Spain
        • SB Investigative Site
      • Oviedo, Spain
        • SB Investigative Site
      • Santiago de Compostela, Spain
        • SB Investigative Site
      • Seville, Spain
        • SB Investigative Site
      • Valencia, Spain
        • SB Investigative Site
  • Thailand
      • Bangkok, Thailand
        • SB Investigative Site 1
      • Bangkok, Thailand
        • SB Investigative Site 2
      • Bangkok Noi, Thailand
        • SB Investigative Site
      • Khon Kaen, Thailand
        • SB Investigative Site
  • Turkey (Türkiye)
      • Adapazarı, Turkey (Türkiye)
        • SB Investigative Site
      • Ankara, Turkey (Türkiye)
        • SB Investigative Site 1
      • Ankara, Turkey (Türkiye)
        • SB Investigative Site 2
      • Balgat, Turkey (Türkiye)
        • SB Investigative Site
      • Bağcılar, Turkey (Türkiye)
        • SB Investigative Site
      • Istanbul, Turkey (Türkiye)
        • SB Investigative Site
      • Kavaklıdere, Turkey (Türkiye)
        • SB Investigative Site
      • Konak, Turkey (Türkiye)
        • SB Investigative Site
      • Maltepe, Turkey (Türkiye)
        • SB Investigative Site
      • Seyhan, Turkey (Türkiye)
        • SB Investigative Site
      • Sivas, Turkey (Türkiye)
        • SB Investigative Site
      • Çubuk, Turkey (Türkiye)
        • SB Investigative Site
      • İzmit, Turkey (Türkiye)
        • SB Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Have been diagnosed with stage IV non-squamous NSCLC
  • Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
  • Agree to use adequate methods of contraception

Exclusion Criteria:

  • Unable or unwilling to take folic acid and vitamin B12 supplementation
  • Severe hypersensitivity to treatment with another monoclonal antibody, any ingredient contained in SB27 or Keytruda, or any component of platinum-containing compounds or pemetrexed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: SB27
SB27 will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles).
Drug: SB27
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks
Active Comparator: Keytruda
Keytruda will be administered followed by Pemetrexed and Carboplatin (Carboplatin will be administered for the first 4 cycles).
Drug: Keytruda
Will be administered intravenously at a fixed dose of 200 mg every 3 weeks

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR) at Week 24
Time Frame: At Week 24
Defined as the proportion of subjects achieving a complete response (CR) or partial response (PR) at Week 24 according to RECIST v1.1
At Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Samsung Bioepis Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 12, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 28, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 28, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 4, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 17, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 13, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SB27-3004

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-small Cell Lung Cancer Stage IV

Clinical Trials on SB27

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings